CPRIT announces New Seed Award for early-stage oncology startups

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Prevention and Research Institute of Texas is unveiling a new award mechanism targeting early-stage oncology startup companies. Under this program, known as the Seed Award, companies can apply for up to $3 million in nondilutive funding to support development of innovative cancer therapeutics, diagnostics or tools.

The Seed Award is designed for projects that are too early in their development to be competitive for CPRIT’s two other Product Development awards: the Texas Company Award and the Company Relocation Award. The goal of the Seed Award is to assist startups in bridging the gap between translational research and product development, thus bringing disruptive cancer-fighting technologies to market.

To qualify for up to $3 million in project funding, companies must currently be based in Texas or commit to relocate to Texas upon receipt of award. Companies interested in this award will need to apply and undergo CPRIT’s peer review process.

Seed Award Requests for Application for FY 2019 Cycle 1 will be released in June 2018, with applications due in August 2018. The award will be announced in February 2019.

Cycle 2s RFAs will be released December 2018, with applications due in February 2019 and award notification in August 2019. Similar schedules are planned for FY 2020 and FY 2021.

Please visit the CPRIT website, and select Grant Information to receive updates on CPRIT funding opportunities.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login